Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of intravenous rhPro-UK thrombolysis in acute ischemic stroke
ChiCTR1800016519Phase 2Completed
- Sponsor
- Xuanwu Hospital
- Start
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant human prourokinase and tissue-plasminogen activator in ischemic stroke (5 arms), sponsored by Xuanwu Hospital. Primary endpoint: Modified Rankin Scale score at 90 days. Started Nov 2016; status: completed.
02
Drugs
recombinant human prourokinasetissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR1800016519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016519.